Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof

US12358983B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Jan Endell · Munich, DE
• Konstantin Petropoulos · Munich, DE
• Peter Kelemen · Munich, DE
• Rainer Boxhammer · Aying, DE
• Markus Rückert · Kottgeisering, DE

Key dates

• Filing date: Oct 27, 2017
• Grant date: Jul 15, 2025
• Expiry date: Jan 20, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.